The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

FDA approves RHHBY's Susvimo for diabetic retinopathy, its third indication, offering 9-month relief with one treatment.

Basel: Roche has received approval from the US Food and Drug Administration (FDA) for Susvimo (ranibizumab injection) 100 ...

One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months ...

Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the ...

Diabetic retinopathy affects almost 10 million people in the US and is the third FDA-approved indication for Susvimo, which is also approved for treating neovascular or ‘wet’ age-related macular ...